Evidence map›Paper›PMID 24062991›Full record

ReviewFrontiers in oncology2013

PML in the Brain: From Development to Degeneration.

Erica Korb, Steven Finkbeiner

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Erica KorbGladstone Institutes of Neurological Disease , San Francisco, CA , USA ; Neuroscience Graduate Program, University of California , San Francisco, CA , USA.
Steven Finkbeiner
Gladstone Institutes · US

Funding

MECHANISMS OF HUNTINGTIN-INDUCED NEURODEGENERATIONR01NS039074 · NINDS · J. DAVID GLADSTONE INSTITUTES · PI FINKBEINER, STEVEN M · 2000 to 2017
$5.4M
Regulation and Function of Arc in the NucleusF31MH087009 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KORB, ERICA MEGAN · 2010 to 2011
$62k
NIMH NIH HHS F31 MH087009NINDS NIH HHS R01 NS039074
6 · The paper itself

Abstract

The promyelocytic leukemia (PML) protein is the main component of PML nuclear bodies, which have many functions in a wide range of cell types. Until recently, PML was not known to have a function in the nervous system or even be expressed in the brain. However, recent reports have changed that view. PML is found in neurons and functions in many aspects of the nervous system, including brain development, circadian rhythms, plasticity, and the response to proteins that cause neurodegenerative disorders. While the investigation of PML in the brain is still in its infancy, it promises to be a fascinating subject that will contribute to our understanding of the brain. Here we summarize what is known about PML expression and function in the brain and highlight both discrepancies in the field and areas that are particularly important to future research.

Indexed as

Arccircadian rhythmsneocortex developmentneural progenitor cellsneurodegenerationPMLSCNsynaptic plasticity

Identifiers

PMID24062991
PMCPMC3775456
OpenAlexW2136792144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.